Table 1.
Characteristics of studies.
| References | Year | Characteristic in baseline | Intervention | Outcome measures |
Follow-up time |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Omega-3 | Control | ||||||||||
| Age | Sex, Male n [%] | N | Age | Sex, Male n [%] | N | Omega-3 | Control | ||||
| Abdulhamied Alfaddagh (24) | 2017 | 62.6 ± 7.5 | 84 [86.6%] | 122 | 62.4 ± 7.8 | 104 [85.2%] | 97 | DHA | Placebo | c.d.e.f. | 30-Month |
| Abdulhamied Alfaddagh (35) | 2019 | 63.5 ± 7.8 | 110 [82.7%] | 133 | 62.1 ± 7.7 | 72 [84.7%] | 85 | DHA | Placebo | d.e.f. | 30-Month |
| Arja T. Erkkilä (45) | 2006 | N a | N | 114 | N | N | 114 | EPA and DHA | Placebo | i. | 3.2 ± 0.6 Years |
| Clemens von Schacky (42) | 1999 | 57.8 ± 9.7 | 91 [82.0%] | 29 | 58.9 ± 8.1 | 88 [78.6%] | 29 | DHA | Placebo | i. | 2 Years |
| Elsa M Hjerkinn (36) | 2005 | 70 [64-76] | N | 124 | 70 [64-76] | N | 119 | EPA and DHA | Placebo | g.i. | 3 Years |
| F. M. Sacks (37) | 1995 | 62 ± 7 | 29 [93.5%] | 179/31b | 62 ± 7 | 26 [92.9%] | 126/28c | DHA | Placebo | i. | 2.4 Years |
| Matthew J. Budoff (38) | 2020 | 56.5 ± 8.9 | 17 [54.8%] | 31 | 58.3 ± 8.6 | 20 [54.1%] | 37 | IPE | Placebo | c.d.e.f. | 18–24 Months |
| O. Johansen (39) | 1999 | 57.3 [43-74] | 18 [78.3%] | 23 | 57.7 [40-73] | 21 [67.7%] | 31 | DHA | Placebo | g.i. | 6 Months |
| S. L. Seierstad (40) | 2005 | 58 [46-74] | 17 [85%] | 20 | 63 [52-75] | 18 [94.7%] | 20 | DHA | Placebo | g. | NA |
| Tetsu Watanabe (41) | 2017 | 67 ± 10 | 78 [80%] | 97 | 68 ± 10 | 81 [84%] | 96 | EPA | Placebo | c.d.e.f. | 6–8 months |
| Toshiyuki Niki (44) | 2016 | 68.1 ± 10.1 | 21 [72%] | 29 | 69.4 ± 10.7 | 19 [63%] | 30 | EPA | Placebo | c.d.e.f. | 6 months |
| I. Seljeflot (43) | 1998 | 49.5 [41-57] | N | 22 | 48 [70-112] | N | 19 | DHA | Placebo | g.i. | 6 weeks |
| Jinhee Ahn (25) | 2016 | 59.6 ± 9.1 | 24 [63.2] | 38 | 60.7 ± 0.8 | 26 [72.2] | 36 | EPA and DHA | Placebo | d,i. | 12 Months |
| Yoichiro Sugizaki (34) | 2020 | 70.8 ± 7.7 | 17 [81.0] | 21 | 75.3 ± 8.8 | 16 [76.2] | 21 | EPA+Rosuvastatin | Placebo | i. | 12Months |
| Yoko Kita (33) | 2020 | 63 [55-73] | 27 [87] | 31 | 63 [55-73] | 24 [77] | 31 | EPA | Placebo | d. | 8 Months |
| Tetsuya Amano (32) | 2011 | 70 ± 10 | 82 [43] | 58 | 70 ± 10 | 82 [43] | 58 | EPA <1.9 | EPA≥1.9 | d,e,g,i | NA |
| Leah E. Gillingham (27) | 2011 | N | N | 36 | N | N | 36 | Flaxseed | High-oleic rapeseed oil diet | g. | 2 Years |
| M. Mirfatahi (29) | 2016 | 68.0 ± 3.0 | 12.0 [71.0%] | 17 | 59.0 ± 4.0 | 10.0 [59.0%] | 17 | Flaxseed oil | Placebo | g. | 8 Weeks |
| Paula Berstad (30) | 2003 | 70 ± 3 | N | 47 | 70 ± 3 | N | 42 | Dietary + VLC n-3 | Dietary intervention | g. | 3 Years |
| Kaeng W. Lee (26) | 2005 | 59 ± 10 | 35 [95] | 37 | 55 ± 10 | 36 [96] | 40 | Omacor | Usual care | i. | 3 Month |
| Melinda Phang (28) | 2014 | N | N | 31 | N | N | 32 | EPA and DHA | Placebo | i. | 4 Weeks |
| Szu-Yun Wu (31) | 2014 | N | N | 84 | N | N | 84 | DHA | Placebo | g | 8 Weeks |
*Data are expressed in mean ± SD or interquartile range.
aN means none.
bNumber of samples of lesions/population size.
cAssociations of ω-3 PUFAs supplementation and coronary atherosclerotic plaques.
dChange in volume of the lipid plaques.
eChange in volume of the fiber plaques.
fChange in volume of the calcified plaques.
gContent of sVCAM-1 in peripheral blood.
hContent of von Willebrand factor in peripheral blood.
iThe diameter of the narrowest segment of Cas.